neuropathic%20pain
NEUROPATHIC PAIN
Neuropathic pain is the sensation of pain due to abnormal discharges of impaired or injured neural structures in the peripheral &/or central nervous system.
It is characterized by hyperesthesia, hyperalgesia and allodynia.
Common neuropathic pain syndromes are central neuropathic pain, painful diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, postsurgical neuropathic pain, HIV-related neuropathy, lumbosacral radiculopathy and complex regional pain syndrome.

Surgical Intervention

Trigeminal Neuralgia (TN)

  • For patients with trigeminal neuralgia refractory to medical therapy, early surgical therapy may be considered
  • Prior to considering surgery, eligible patients should have an MRI to eliminate other causes of compression of the trigeminal nerve
  • Peripheral Techniques
    • Involve blocking or destruction of portions of the trigeminal nerve distal to the Gasserian ganglion
    • Low morbidity but 50% have pain recurrence after 1 year
  • Percutaneous Procedures on Gasserian Ganglion
    • Preferred for elderly patients, those with multiple sclerosis (MS), with impaired contralateral hearing, and those with recurrent pain after microvascular decompression
    • Eg radiofrequency thermocoagulation, balloon compression rhizotomy, percutaneous retro-Gasserian glycerol rhizotomy
    • After percutaneous trigeminal radiofrequency, initial pain relief can be achieved in 98% of patients & 15-20% of patients may experience recurrence in 12 months
    • Observational studies have shown that radiofrequency thermocoagulation produces higher rates of complete pain relief but is also associated with higher rates of facial numbness and corneal insensitivity
      • Severe facial numbness/anesthesia dolorosa and corneal numbness with keratitis occur in around 4% of patients
  • Microvascular Decompression
    • Preferred procedure for young patients with typical trigeminal neuralgia
    • Major neurosurgical procedure involving craniotomy to reach the trigeminal nerve in the posterior fossa
    • Vessels compressing the nerve are identified and moved out of contact
    • Provides longest duration of pain relief while preserving facial sensation
    • Complications include aseptic meningitis, hearing loss, cerebrospinal fluid (CSF) leaks, infarcts, hematomas, transient diplopia and sensory loss
    • Associated with 0.5% mortality rate and 3-29% facial numbness rates
    • Increased risk for severe complications in older age groups
  • Gamma Knife Stereotactic Radiosurgery
    • Least invasive procedure for trigeminal neuralgia
    • Treatment option for patients with comorbidities, high-risk medical illness or pain refractory to prior surgical procedures
    • Aims a focused beam of radiation at the trigeminal root in the posterior fossa
    • In a study, it showed that adequate pain relief were 75%, 60% & 58% at 1, 3, & 5 years, respectively
      • Onset of pain relief is variable with an average time of 1 month or median time of 2 weeks after treatment
    • Most common adverse effect is trigeminal nerve sensory dysfunction eg facial numbness, paresthesia
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 2 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.